• The change from Baseline to Week 4 (or end of treatment) in the IGA. [ Time Frame: from Baseline to Week 4 ] [ Designated as safety issue: No ]
• The change from Baseline to Week 4 (or end of treatment) in the calculated EASI score. [ Time Frame: from Baseline to Week 4 ] [ Designated as safety issue: No ]

• The change from Baseline to Week 4 (or end of treatment) in the IGA. [ Time Frame: from Baseline to Week 4 ] [ Designated as safety issue: No ]
• The change from Baseline to Week 4 (or end of treatment) in the calculated EASI score. [ Time Frame: from Baseline to Week 4 . ] [ Designated as safety issue: No ]

The purpose of this research study is to better understand how the study drug works when people use it to treat atopic dermatitis.

To evaluate adherence to topical therapy using adherence data collected by the MEMS cap (Medication Electronic Monitoring System) in pediatric patients with atopic dermatitis (AD) and the impact of a return visit.

Inclusion Criteria:

1. Male or female subjects age 2-15.
2. Stable or worsening atopic dermatitis affecting 5% or greater body surface area. Face and genital areas can be included in the body surface area determination and treatment area.
3. The ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study.
4. The ability to understand and sign a written informed consent/assent form, which must be obtained prior to treatment.

Exclusion Criteria:

1. Known allergy to tacrolimus or to any component of the formulations.
2. The use of systemic therapy for atopic dermatitis within the past 4 weeks.
3. Use of prescription topical therapy for atopic dermatitis (e.g., corticosteroids or retinoids) within the past 2 weeks.
4. Use of any investigational therapy within the past 4 weeks.
5. Pregnant females, females who are breast feeding, or females of childbearing potential who are not practicing an acceptable method of birth control (abstinence, birth control pill/patch, barrier with spermicidal jelly, IUD, etc.), as determined by the investigator. Acceptable contraception must be used during the entire study. A pregnancy test will be performed on females of childbearing potential at baseline and at week 4.
6. Any other condition which, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.